Remove tag ai
article thumbnail

Hospitals want to buy doctors’ happiness with Nuance’s AI scribe. What they’re paying varies

STAT

Microsoft-owned Nuance Communications sells its AI medical scribe platform to health care providers on a simple promise: If they shell out big bucks for the high-tech product, they can decrease doctor burnout and ultimately make more money by enabling doctors to see more patients. Read the rest…

article thumbnail

Pharma Pulse 3/29/24: Super Micro’s AI Boom Carries a Big Price Tag, Leveraging Digital Tools to Optimize Manufacturing & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (March 20 - 24, 2023)

PharmaShots

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 64
article thumbnail

AI hiring levels in the pharmaceutical industry rose in May 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for AI related positions kept relatively steady in May 2022 compared with the equivalent month last year, with 39.3% This latest figure was higher than the 39% of companies who were hiring for AI related jobs a year ago but a decrease compared to the figure of 43.6% in April 2022.

article thumbnail

PharmaShots Weekly Snapshots (March 20 - 24, 2023)

PharmaShots

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40
article thumbnail

PharmaShots Weekly Snapshots (May 29 - June 02, 2023)

PharmaShots

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

FDA 40
article thumbnail

Jolly Good/Teijin Pharma develop VR digital therapeutics for depression

pharmaphorum

Jolly Good is a medical technology company that develops VR solutions and AI-based medical and welfare services that analyse user behaviour in the VR space. However Nokia famously ran into trouble when it tried to develop VR products for digital health and its OZO camera failed to catch on, mainly because of a high $60,000 price tag.

Hospitals 121